Loading…
Herbalife Ltd.
$1.3B
Market Cap
5.9
P/E
0.23
PEG
24.4%
ROCE
-34.8%
ROE
-4.18
D/E
9.6%
OPM
-37.9%
% from 52W High
76
α RS
🔍 HLF is showing a sector-leadership setup because Sector RRG has Consumer Staples in the Leading quadrant with the trail still strengthening, RS Rating is 76, and it's hugging the 21 EMA. Net: Broad signal stack, not a recommendation. ? RRG RS Rating Technicals
Sources
Consumer Staples in Leading quadrant · RS Rating 76 · hugging 21 EMA
⚖️ Compare 🔒 Generate Report 🔒 Research Packet 📚 Guides
🌏 Global Investor Returns
Currency-adjusted total returns for HLF including FX impact
🌏
Click 🌏 Returns tab to load data
📈 Price History
Ratio Health
Excellent
Good
Average
Poor
By Category
📊 Sector Averages
About

Herbalife Ltd., together with its subsidiaries, provides health and wellness products in North America, Mexico, South and Central America, Europe, the Middle East, Africa, China, and the Asia Pacific.

Key Ratios Snapshot
📈 Growth Pattern
📊 Quick Scorecard
Loading…
⭐ Superinvestors Holding HLF
View All Superinvestors →
Manager Shares Value % of Fund Period
Seth Klarman Baupost Group 9.26M $136.3M 2.66% Mar 2026
Jim Simons Renaissance Technologies LLC 5.50M $81.0M 0.13% Mar 2026
Steve Cohen Point72 Asset Management 129.2K $1.9M 0.00% Mar 2026

SEC Form 13F data. 45-day lag from quarter end.

🔒
Premium Feature
AI-generated 10-section company profile — business model, financials, strengths, risks & management quality
Upgrade to Premium
Already a member? Log in
📐
3-Statement Financial Model
Bear / Base / Bull projections · DCF fair value · Reverse-DCF
Open Model →
📊 MIXED Herbalife Q1 net sales $1.3B, up 7.8% YoY, adjusted EBITDA $176M
Revenue & Profitability
First quarter 2026 net sales totaled $1.3 billion, up 7.8% reported and 5.4% on a constant currency basis, exceeding guidance of 3%-7% growth. Adjusted EBITDA was $176 million (above the $155-175 million guidance), with an adjusted EBITDA margin of 13.3%. Net income attributable to Herbalife was $62 million, adjusted net income $69 million, and adjusted diluted EPS $0.64 (including a $0.03 FX headwind). Operating cash flow was $114 million.
Outlook
Management sees strong industry demand for personalized nutrition, driven by rising consumer expectations from AI, wearables, and at-home diagnostics. They expect year-over-year net sales growth to continue for the remainder of 2026, with momentum in India sustained beyond the GST reduction anniversary. Macro headwinds include higher oil prices (absorbed without price increases) and FX volatility; tailwinds include the ongoing GST benefit in India and new product launches.
Growth Drivers
Key growth levers discussed include: 1) India, which achieved record quarterly sales for the second consecutive quarter ($275 million, up 32% reported, 39% local currency) driven by the GST rate reduction and distributor leadership training. 2) Latin America, delivering its third consecutive quarter of double-digit reported growth (up 17%). 3) The upcoming launch of Bioniq personalized supplements in 11 European countries (late June) and the U.S. (July). 4) Pro2col beta expansion across 10 EMEA markets, with an enhanced version planned for the North America Extravaganza in July. 5) A multi-year packaging redesign to modernize the brand.
Balance Sheet & CapEx
First quarter 2026 capital expenditures were $11 million (low end of guidance), with some spending shifted to Q2. Full-year 2026 CapEx guidance is $50-80 million. Capitalized SaaS implementation costs (incremental) are expected to be $35-55 million. The $55 million acquisition of Bioniq (base consideration over five years, plus potential $95 million contingent payments) is consistent with disciplined investment in personalized nutrition capabilities.
Margins
Adjusted EBITDA margin for Q1 2026 was 13.3%, down 20 basis points year-over-year but up 240 basis points on a two-year stacked basis (including ~70 bps FX headwind). Gross profit margin was 77.9%, down 40 bps year-over-year, driven by input cost inflation (50 bps), unfavorable mix (30 bps), FX (50 bps), partially offset by pricing benefits (70 bps) and lower inventory write-downs (40 bps). Management expects full-year adjusted EBITDA of $675-705 million (both reported and constant currency), with India GST-related costs creating a 40-50 bps margin headwind.
Key Risks
Risks flagged include: foreign exchange volatility (Q1 FX was a ~$5 million EBITDA headwind and 70 bps margin headwind); higher oil prices (expected to be absorbed, not material); India GST-related net incremental costs of ~$20-25 million for full-year 2026; EMEA weakness with an 11% volume decline; China volume decline of 18% (though small at <5% of sales); and unusual weather in North America that impacted Nutrition Club operations in January/February.
Generated by AI · Q1 2026 results · Not investment advice
🔒
Free Account Required

Create a free Finmagine account to access Finmagine™ Scorecard.

See how this company scores across 5 dimensions — Financial Health, Growth Prospects, Competitive Position, Management Quality, and Valuation — powered by 30+ computed ratios.

Create Free AccountLog In
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Ask AI.

Get 25 expert AI analysis templates — Business KPIs, Comprehensive, Forensic Governance, Peer Comparison, Risk-Reward, Full Research Report, IPO Decoder, Red Flag Detector, and more — ready to paste into ChatGPT, Claude, Gemini, or Perplexity.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Peer Comparison.

Compare this company side-by-side against its sector peers with financial metrics, ratio benchmarking, and relative performance across all key dimensions.

Upgrade to PremiumCreate Free Account
✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter
🔍
🔎 See cross-company document search → ?
📞 Earnings Call Transcripts (5)
Q2 2026 Q2 2026 2026-08-05
Net sales grew 5.4% year-over-year to $1.3B, with strong adjusted EBITDA and robust cash flow. Strategic investments in personalized nutrition and digital platforms are driving growth, while disciplined capital allocation and a leadership transition position the company for continued momentum.
Q1 2026 Q1 2026 2026-05-06
Q1 2026 net sales and adjusted EBITDA exceeded guidance, driven by strong growth in India and Latin America, while debt refinancing improved financial flexibility and reduced interest costs. Strategic acquisitions and a focus on personalized nutrition position the company for continued growth.
Q4 2025 Q4 2025 2026-02-18
Delivered strong Q4 and full-year 2025 growth, with net sales up 6.3% in Q4 and adjusted EBITDA margin expansion. Innovation, digital transformation, and a major partnership with Cristiano Ronaldo position the company for continued growth in 2026, with net sales and EBITDA guidance reflecting ongoing momentum.
Q3 2025 Q3 2025 2025-11-05
Q3 2025 saw a return to net sales growth globally and in North America, with strong cash flow, reduced leverage, and robust product innovation. Four of five regions posted sales growth, and new digital and personalized wellness initiatives are driving engagement and future subscription revenue.
Q2 2025 Q2 2025 2025-08-06
Q2 2025 net sales were $1.3B, down 1.7% year-over-year but flat on a constant currency basis, with adjusted EBITDA exceeding guidance. Product innovation and digital transformation are driving momentum, especially in North America, and full-year guidance has been raised.
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Catalyst Timeline.

Every result, order win, insider trade, ECS update, earnings-call, and SEC announcement for this company — in one chronological lane.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Full Report.

Read the complete Finmagine™ investment research report — comprehensive fundamental analysis, business model assessment, competitive positioning, and investment recommendation.

Upgrade to PremiumCreate Free Account

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯
Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.
📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

Financial Model
Projections are built from each company's audited annual financials (Income Statement, Balance Sheet, Cash Flow) over the last 5 fiscal years. Forward assumptions — revenue growth %, EBITDA margin, D&A (USD millions), interest expense, tax rate, and capex — are AI-generated using historical context and refreshed twice a year: after the December results season and after the September/Q4 results season.

DCF Valuation
Fair Value = Σ(FCFt / (1+WACC)t) + Terminal Value. Terminal Value uses the Gordon Growth Model: FCF5 × (1+g) / (WACC−g). Default WACC: 10% (US risk-free ~4.5%, equity risk premium ~5.5%). Default terminal growth: 3% (long-run US nominal GDP proxy).

CAGR Tracker
Expected 5-year CAGR = (DCF Fair Value / Current Price)1/5 − 1. Assumes fair value is reached in exactly 5 years — a mechanical estimate only.

Data Sources & Limitations
Financial statements sourced from public filings. Prices updated daily. Forward assumptions are AI-generated. All monetary values in USD millions. Non-US ADR companies may have currency conversion inaccuracies. Models are point-in-time and do not update intra-quarter or account for M&A, macro shocks, or extraordinary items.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.